A5081825777- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- DNA and Nucleic Acid Chemistry
- DNA Repair Mechanisms
- PARP inhibition in cancer therapy
- Breast Cancer Treatment Studies
- Radiation Effects and Dosimetry
- Radiopharmaceutical Chemistry and Applications
- Cancer-related Molecular Pathways
- RNA and protein synthesis mechanisms
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer-related cognitive impairment studies
- Paleontology and Stratigraphy of Fossils
- Graphene and Nanomaterials Applications
- Monoclonal and Polyclonal Antibodies Research
- Geochemistry and Elemental Analysis
- Colorectal Cancer Treatments and Studies
- Breast Lesions and Carcinomas
Institut Català d'Oncologia
2018-2025
Institut d'Investigació Biomédica de Bellvitge
2022-2025
Duran i Reynals Hospital
2019-2024
University of Puerto Rico at Río Piedras
2024
Memorial Sloan Kettering Cancer Center
2023
GEICAM – Spanish Breast Cancer Group
2022-2023
Hospital de Sant Joan Despí Moisès Broggi
2019-2022
Bellvitge University Hospital
2022
Louisiana State University Agricultural Center
2019
Hospital Universitario Virgen del Rocío
2019
An earlier analysis of this phase 3 trial showed that the addition a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided greater benefit with regard progression-free survival than alone in premenopausal or perimenopausal patients advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report results protocol-specified interim key secondary end point overall survival.We randomly assigned receive either...
Abstract Purpose: Ribociclib plus endocrine therapy (ET) demonstrated a statistically significant progression-free survival and overall (OS) benefit in the phase III MONALEESA-7 trial of pre-/perimenopausal patients with hormone receptor (HR)-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC). The median OS was not reached ribociclib arm protocol-specified final analysis; we hence performed an exploratory additional outcomes analysis extended follow-up (median, 53.5 months)....
This analysis evaluated patient-reported outcomes (PROs) to assess health-related quality of life (HRQoL) in the phase III MONALEESA-7 trial, which previously demonstrated improvements progression-free survival (PFS) and overall (OS) with ribociclib (cyclin-dependent kinase 4/6 inhibitor) + endocrine therapy (ET) compared placebo ET pre- perimenopausal patients hormone-receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer (ABC).The European Organisation for Research Treatment...
Abstract Background Ladiratuzumab vedotin (LV) is an investigational anti-LIV-1 antibody-drug conjugate with a protease-cleavable linker to monomethyl auristatin E (MMAE). LIV-1 highly expressed in metastatic triple negative breast cancer (TNBC). LV mediated delivery of MMAE drives antitumor activity through cytotoxic cell killing and has been shown induce immunogenic death (ICD). monotherapy demonstrated encouraging TNBC. Anti-PD-(L)1 agents are emerging as part the TNBC treatment paradigm...
This analysis evaluated the genomic landscape of premenopausal patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer association genetic alterations response to ribociclib in phase III MONALEESA-7 trial.Premenopausal were randomly assigned 1:1 receive endocrine therapy plus or placebo. Plasma collected at baseline was sequenced using targeted next-generation sequencing for approximately 600 relevant genes. The circulating tumor...
Giredestrant is an investigational next-generation, oral, selective estrogen receptor antagonist and degrader for the treatment of receptor-positive (ER+) breast cancer. We present primary analysis results phase Ia/b GO39932 study (NCT03332797).
Abstract Background: MONALEESA-7 (NCT02278120), the first large randomized phase III clinical trial dedicated to investigating a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus ET vs + placebo (PBO) in pre- or perimenopausal patients with HR+/HER2− ABC, previously demonstrated statistically significant improvement OS addition of ribociclib (RIB) PBO (median, not reached 40.9 months; HR, 0.71 [95% CI, 0.54-0.95]; P = .00973; Im SA, et al. N Engl J Med. 2019). This concluded...
Abstract Purpose: AZD8701 uses next-generation antisense oligonucleotide (ASO) technology to selectively reduce human forkhead box P3 (FOXP3) expression in regulatory T cells, reversing their immunosuppressive function. FOXP3 ASOs alone or with programmed cell death protein (ligand) 1 (PD-[L]1) inhibition attenuated tumor growth mice. We report a phase I study of combined durvalumab patients advanced solid tumors. Methods: Eligible had tumors and received prior standard-of-care treatment...
Background/Objectives: Few large cohorts with relatively uniform treatment approaches and long-term follow-up are available for assessing clinical outcomes breast cancer (BC) patients. The Institut Català d’Oncologia (ICO) Breast Cancer Cohort was designed to well characterize patterns overall survival at 5 10 years, a particular focus on patients < 40 ≥70 years old, age groups often underrepresented in trials. Methods: In this retrospective, observational study, we included all...
<p>Baseline patient and disease characteristics (safety population).</p>
<p>Safety summary.</p>
<div>AbstractPurpose:<p>AZD8701 uses next-generation antisense oligonucleotide (ASO) technology to selectively reduce human forkhead box P3 (FOXP3) expression in regulatory T cells, reversing their immunosuppressive function. <i>FOXP3</i> ASO alone or with PD-(L)1 inhibition attenuated tumor growth mice. We report a phase I study of AZD8701 combined durvalumab patients advanced solid tumors.</p>Patients and Methods:<p>Eligible had tumors received prior...
<p>Definition of dose-limiting toxicities (DLT), Inclusion and exclusion criteria, T, B, natural killer (TBNK) cell assay, Proliferating T miRNAscope in situ hybridization HALO image analysis</p>
<p>Changes in liver function parameters over time patients treated with (<b>A</b>) AZD8701 monotherapy and (<b>B</b>) durvalumab. ALP, alkaline phosphatase.</p>